CUE - CIK 0001645460
Cue Biopharma, Inc. trades as CUE. In its fiscal 2025 annual report the company posted revenue of $27.47M, up 195.7% from the prior year and net income of -$26.60M. This page tracks Cue Biopharma, Inc. through 496 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years Cue Biopharma, Inc.'s revenue grew from $1.14M to $27.47M, a compound annual growth rate of 57.5%. Net profit margin expanded from -3411.5% to -96.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Proxy statement | DEF 14A | 2026-05-21 |
| D | - | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 |
| PRE 14A | - | 2026-05-11 |
| New insider ownership | 3 | 2026-05-07 |
| Insider trade | 4 | 2026-05-07 |
| Employee stock plan | S-8 | 2026-05-01 |
The largest companies sharing Cue Biopharma, Inc.'s SEC industry classification (pharmaceutical preparations).
Cue Biopharma, Inc. reported revenue of $27.47M for fiscal year 2025, an increase of 195.7% year over year.
In its latest fiscal year Cue Biopharma, Inc. reported a net loss of $26.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.